Page last updated: 2024-08-25

lamifiban and Coronary Disease

lamifiban has been researched along with Coronary Disease in 22 studies

Research

Studies (22)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	9 (40.91)	18.2507
2000's	13 (59.09)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Berdan, L; Califf, RM; Dyke, C; Gallup, D; Harrington, RA; Lauer, MS; Mahaffey, KW; Mänttäri, M; Moliterno, DJ; Mukherjee, D; Pieper, KS; Roe, MT; Topol, EJ; White, HD; Yadav, JS	1
Armstrong, PW; Califf, RM; Christenson, RH; Fu, Y; Harrington, RA; Hasselblad, V; Kaul, P; Mahaffey, KW; Newby, LK; Ohman, EM; Topol, EJ; Van de Werf, F	1
Armstrong, PW; Califf, RM; Fu, Y; Harrington, RA; Hersi, A; Mahaffey, KW; Van de Werf, F; Wong, B	1
Bhapkar, MV; Califf, RM; Davis, CG; Granger, CB; Harrington, RA; Hochman, JS; Moliterno, DJ; Newby, LK; Simes, RJ; Topol, EJ; Van de Werf, F	1
Boersma, E; Westerhout, CM	2
Verheugt, FW	1
Gawaz, M; Neumann, FJ; Schömig, A	1
Adgey, AA	2
Ferguson, JJ; Lau, TK	1
Armstrong, PW; Braunwald, E; Califf, RM; Gibler, WB; Hamm, CW; Maseri, A; Simoons, ML; Van de Werf, F	1
Alexander, JH; Harrington, RA	1
Kaluza, G; Kleiman, NS; Mazur, W	1
Phillips, J; Stouffer, GA; Subbarao, VD	1
Califf, RM; Lincoff, AM; Topol, EJ	1
Blankenship, JC; Frey, CM; Memon, MA; Menapace, FJ; Wood, GC	1
Jang, IK; Sabatine, MS	1
Berkowitz, SD	1
Armstrong, PW; Califf, RM; Christenson, RH; Harrington, RA; Hasselblad, V; Moliterno, DJ; Newby, LK; Ohman, EM; Pfisterer, M; Topol, EJ; Van De Werf, F; White, HD	1
SoRelle, R	1

Reviews

14 review(s) available for lamifiban and Coronary Disease

Article	Year
Risk-benefit analysis of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Expert opinion on drug safety, 2003, Volume: 2, Issue:1 Topics: Abciximab; Acetates; Acute Disease; Antibodies, Monoclonal; Coronary Disease; Drug Evaluation; Eptifibatide; Guidelines as Topic; Humans; Immunoglobulin Fab Fragments; Incidence; Injections, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Tirofiban; Treatment Outcome; Tyrosine	2003
Intravenous glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: lessons from recently conducted randomized clinical trials. Current opinion in investigational drugs (London, England : 2000), 2004, Volume: 5, Issue:3 Topics: Abciximab; Acetates; Acute Disease; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine	2004
[Platelet membrane glycoproteins as site of pharmacological intervention in the treatment of coronary disease]. Deutsche medizinische Wochenschrift (1946), 1997, Oct-02, Volume: 122, Issue:40 Topics: Abciximab; Acetates; Alkynes; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Binding Sites; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Coronary Disease; Double-Blind Method; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Platelet Membrane Glycoproteins; Randomized Controlled Trials as Topic; Receptors, Antigen, B-Cell; Receptors, Cell Surface; Time Factors; Tirofiban; Tyrosine	1997
An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. American heart journal, 1998, Volume: 135, Issue:4 Topics: Abciximab; Acetates; Antibodies, Monoclonal; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Eptifibatide; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Treatment Outcome; Tyrosine	1998
New antiplatelet agents for acute coronary syndromes. American heart journal, 1998, Volume: 135, Issue:5 Pt 2 Su Topics: Abciximab; Acetates; Acute Disease; Antibodies, Monoclonal; Blood Platelets; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine	1998
An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. European heart journal, 1998, Volume: 19 Suppl D Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Atherectomy, Coronary; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Survival Analysis; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine	1998
Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. European heart journal, 1998, Volume: 19 Suppl D Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine	1998
Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. Drugs, 1998, Volume: 56, Issue:6 Topics: Acetates; Acute Disease; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Eptifibatide; Heparin; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine	1998
Antiplatelet therapy for treatment of acute coronary syndromes. Cardiology clinics, 1999, Volume: 17, Issue:2 Topics: Abciximab; Acetates; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine; Vascular Patency	1999
Use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. The American journal of the medical sciences, 1999, Volume: 318, Issue:2 Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Angina, Unstable; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine	1999
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. Journal of the American College of Cardiology, 2000, Volume: 35, Issue:5 Topics: Abciximab; Acetates; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Combined Modality Therapy; Coronary Disease; Drug Monitoring; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Myocardial Infarction; Patient Selection; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Recurrence; Risk Factors; Tirofiban; Treatment Outcome; Tyrosine	2000
Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials. The American journal of medicine, 2000, Aug-15, Volume: 109, Issue:3 Topics: Abciximab; Acetates; Acute Disease; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Eptifibatide; Heparin; Humans; Immunoglobulin Fab Fragments; Incidence; Infusions, Intravenous; Intracranial Hemorrhages; Odds Ratio; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Syndrome; Tirofiban; Tyrosine	2000
The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. The American journal of medicine, 2000, Aug-15, Volume: 109, Issue:3 Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Alanine; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Syndrome; Thrombocytopenia; Thrombolytic Therapy; Tirofiban; Tyrosine	2000
Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease. Haemostasis, 2000, Volume: 30 Suppl 3 Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Coronary Artery Bypass; Coronary Disease; Drug Approval; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Mice; Multicenter Studies as Topic; Myocardial Ischemia; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Recurrence; Safety; Single-Blind Method; Stents; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine; United States; United States Food and Drug Administration	2000

Trials

6 trial(s) available for lamifiban and Coronary Disease

Article	Year
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). American heart journal, 2002, Volume: 144, Issue:6 Topics: Acetates; Acute Disease; Aged; Anticoagulants; Coronary Disease; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Myocardial Revascularization; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Survival Analysis; Tyrosine	2002
Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. Journal of the American College of Cardiology, 2003, Feb-05, Volume: 41, Issue:3 Topics: Acetates; Acute Disease; Aged; Coronary Disease; Electrocardiography; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Risk Assessment; Syndrome; Time Factors; Troponin T; Tyrosine	2003
Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission? European heart journal, 2003, Volume: 24, Issue:6 Topics: Acetates; Acute Disease; Aged; Arrhythmias, Cardiac; Coronary Disease; Disease-Free Survival; Electrocardiography; Female; Hospitalization; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Survival Analysis; Troponin T; Tyrosine	2003
An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A. Journal of thrombosis and thrombolysis, 2002, Volume: 14, Issue:1 Topics: Acetates; Acute Disease; Aged; Aged, 80 and over; Coronary Disease; Female; Heparin; Humans; Infusions, Intravenous; Logistic Models; Male; Middle Aged; Monitoring, Physiologic; Odds Ratio; Partial Thromboplastin Time; Point-of-Care Systems; Syndrome; Tyrosine	2002
Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation, 2001, Jun-19, Volume: 103, Issue:24 Topics: Acetates; Acute Disease; Aged; Coronary Disease; Double-Blind Method; Electrocardiography; Endpoint Determination; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Odds Ratio; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Secondary Prevention; Survival Rate; Treatment Outcome; Troponin T; Tyrosine	2001
Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation, 2002, Jan-22, Volume: 105, Issue:3 Topics: Acetates; Acute Disease; Aged; Coronary Disease; Double-Blind Method; Endpoint Determination; Female; Hemorrhage; Humans; Incidence; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Titrimetry; Treatment Outcome; Tyrosine	2002

Other Studies

2 other study(ies) available for lamifiban and Coronary Disease

Article	Year
In search of a superaspirin for the heart. Lancet (London, England), 1997, May-17, Volume: 349, Issue:9063 Topics: Abciximab; Acetates; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine	1997
Platelet glycoprotein IIb/IIIa inhibitor effect examined in 2 studies. Circulation, 2002, Jan-22, Volume: 105, Issue:3 Topics: Acetates; Acute Disease; Angina, Unstable; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Eptifibatide; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Syndrome; Treatment Outcome; Tyrosine	2002